AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34543687 — intervention group
Group type: COMPARATOR
Intervention: Standard BP treatment (systolic BP <140 mm Hg)
Number of subjects: 716
Study 32658621 — intervention group
Group type: EXPERIMENTAL
Intervention: NCWS patients
Number of subjects: 12
Study 32658621 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 32318704 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-positive patients with lower HBsAg levels
Number of subjects: 2779
Study 32318704 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-specific HBsAg cutoffs
Number of subjects: 2779
Study 32318704 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic performance of HBsAg cutoffs
Number of subjects: 2779
Study 35363844 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver closed vitrification system (CVS)
Number of subjects: 9
Study 35363844 — intervention group
Group type: COMPARATOR
Intervention: Slow freezing (SF)
Number of subjects: 9
Study 35858179 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior glenoid angle measurement via MRI
Number of subjects: 90
Study 34696811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (brief counseling sessions and low-dose physical activity recommendations)
Number of subjects: 583
Study 34696811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 583
Study 33025448 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacists' knowledge regarding malaria and its treatment
Number of subjects: 293
Study 33025448 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacists' practices regarding antimalarials dispensing
Number of subjects: 293
Study 33025448 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to effective contribution in malaria prevention and treatment
Number of subjects: 293
Study 33025448 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for pharmacists
Number of subjects: 293
Study 35940087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion (0.5 mg/kg)
Number of subjects: 153
Study 35940087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Number of subjects: 153
Study 35940087 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS
Number of subjects: 153
Study 35940087 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control for ketamine)
Number of subjects: 153
Study 35940087 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control for rTMS)
Number of subjects: 153
Study 34521212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) or Interpersonal Psychotherapy (IPT)
Number of subjects: 182
Study 34521212 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 182
Study 34027858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal platelet-rich plasma (PRP) 1 ml
Number of subjects: 64
Study 34027858 — intervention group
Group type: COMPARATOR
Intervention: Intradermal tranexamic acid 4 mg
Number of subjects: 64
Study 34990306 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention (radio drama)
Number of subjects: 2904
Study 34990306 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2904
Study 33118206 — intervention group
Group type: EXPERIMENTAL
Intervention: Best possible selves intervention
Number of subjects: 74
Study 33118206 — intervention group
Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 74
Study 32358867 — intervention group
Group type: EXPERIMENTAL
Intervention: SUMI+ RBCs examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens.
Number of subjects: 541522
Study 32358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanger sequencing and cloning of GYPA gene.
Number of subjects: 541522
Study 35836170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 100
Study 35836170 — intervention group
Group type: COMPARATOR
Intervention: Second ARTA
Number of subjects: 100
Study 33057694 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT-I (Sleep Healthy Using the Internet [SHUTi])
Number of subjects: 303
Study 33057694 — intervention group
Group type: COMPARATOR
Intervention: Patient education (PE)
Number of subjects: 303
Study 35705380 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 IU of hCG plus 450 IU of FSH
Number of subjects: 105
Study 35705380 — intervention group
Group type: COMPARATOR
Intervention: Standard trigger dose of hCG (5,000 or 10,000 IU)
Number of subjects: 105
Study 35221357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic combination of glycopyrrolate, ondansetron, and ephedrine
Number of subjects: 100
Study 35221357 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ephedrine boluses as required)
Number of subjects: 100
Study 34275887 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 30
Study 34275887 — intervention group
Group type: COMPARATOR
Intervention: Sham Kinesio taping (without tension)
Number of subjects: 30
Study 33065708 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sprint training group (RSTG, n = 20) using both weight vest and sled
Number of subjects: 34
Study 33065708 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONTG, n = 14)
Number of subjects: 34
Study 32621696 — intervention group
Group type: EXPERIMENTAL
Intervention: Large container of petroleum jelly
Number of subjects: 128
Study 32621696 — intervention group
Group type: COMPARATOR
Intervention: Small tube of petroleum jelly
Number of subjects: 128
Study 34624179 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise on treadmill
Number of subjects: 38
Study 34624179 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise on cycle ergometer
Number of subjects: 38
Study 34624179 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived exertion during exercise
Number of subjects: 38
Study 35288932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 271
Study 35288932 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 271
Study 35288932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 32911375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 105
Study 32911375 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab or chlorambucil
Number of subjects: 105
Study 33197560 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study 32044091 — intervention group
Group type: COMPARATOR
Intervention: Labelling the number of doses per package
Number of subjects: 870
Study 32044091 — intervention group
Group type: COMPARATOR
Intervention: Traffic Light System labelling
Number of subjects: 870
Study 35984640 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education + intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 126
Study 35984640 — intervention group
Group type: COMPARATOR
Intervention: Standard care with blood glucose monitoring
Number of subjects: 126
Study 34503491 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental sulfur (2% of concentrate dry matter)
Number of subjects: 0
Study 34503491 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea (4% of concentrate dry matter)
Number of subjects: 0
Study 34503491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh cassava root (300 mg of total substrate)
Number of subjects: 0
Study 34406349 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 206
Study 34406349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 33251670 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5988
Study 34997849 — intervention group
Group type: EXPERIMENTAL
Intervention: LED photobiomodulation (PBM) with tooth bleaching
Number of subjects: 64
Study 34997849 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (simulation of irradiation with tooth bleaching)
Number of subjects: 64
Study 33137453 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvre
Number of subjects: 230
Study 33137453 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard protective ventilation
Number of subjects: 230
Study 32857839 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 9215
Study 32857839 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 9215
Study 32857839 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 9215
Study 32857839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9215
Study 36226669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof 1% cream
Number of subjects: 0
Study 36226669 — intervention group
Group type: COMPARATOR
Intervention: Vehicle arm (control)
Number of subjects: 0
Study 34808727 — intervention group
Group type: COMPARATOR
Intervention: Titanium palmar plating (TPP)
Number of subjects: 31
Study 34808727 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK palmar plating (PPP)
Number of subjects: 31
Study 32862716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor added to standard aspirin (80 mg or 100 mg)
Number of subjects: 499
Study 32862716 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to standard aspirin (80 mg or 100 mg)
Number of subjects: 499
Study 35426778 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine supplementation
Number of subjects: 66
Study 35426778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 33648347 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0
Study 33648347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 34670908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal neobladder surgery
Number of subjects: 40
Study 35031896 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 147
Study 35031896 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 147
Study 34130033 — intervention group
Group type: EXPERIMENTAL
Intervention: High n‐3 PUFA, average n‐6 PUFA (H3) diet targeting 1500 mg EPA+DHA/day and 7% of energy from n‐6 linoleic acid (LA)
Number of subjects: 178
Study 34130033 — intervention group
Group type: EXPERIMENTAL
Intervention: High n‐3 PUFA, low‐n‐6 PUFA (H3L6) targeting 1500 mg EPA+DHA/day and <1.8 en% n‐6 LA
Number of subjects: 178
Study 34130033 — intervention group
Group type: COMPARATOR
Intervention: Control diet with typical American intakes of both EPA+DHA (<150 mg/day) and 7 en% from n‐6 LA
Number of subjects: 178
Study 34130033 — intervention group
Group type: EXPERIMENTAL
Intervention: High n‐3 PUFA, average n‐6 PUFA (H3) diet
Number of subjects: 178
Study 34130033 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 178
Study 34130033 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐n‐3 PUFA, low‐n‐6 PUFA (H3L6)
Number of subjects: 178
Study 34130033 — intervention group
Group type: EXPERIMENTAL
Intervention: All diet groups
Number of subjects: 178
Study 35115574 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Interferon (IFN) beta‐1a (10 μg) for 6 days after surgery
Number of subjects: 38
Study 35115574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 35115574 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Interferon (IFN) beta‐1a
Number of subjects: 38
Study 33479268 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 1 mmol L-1
Number of subjects: 9
Study 33479268 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 3 mmol L-1
Number of subjects: 9
Study 33479268 — intervention group
Group type: COMPARATOR
Intervention: Cadmium (Cd) at 50 µmol L-1
Number of subjects: 9
Study 33479268 — intervention group
Group type: COMPARATOR
Intervention: Cadmium (Cd) at 200 µmol L-1
Number of subjects: 9
Study 32769643 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (50 units, injected twice, 3 months apart)
Number of subjects: 88
Study 32769643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injected twice, 3 months apart)
Number of subjects: 88
Study 34462956 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic capsules (Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides) twice per day for 14 days
Number of subjects: 38
Study 34462956 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 38
Study 34462956 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic capsules
Number of subjects: 38
Study 34610580 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 193
Study 34610580 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine/Fluoxetine
Number of subjects: 193
Study 35525480 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF 200/12 μg via DPI
Number of subjects: 36
Study 35525480 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF 400/24 μg via DPI
Number of subjects: 36
Study 35525480 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF 800/48 μg via DPI
Number of subjects: 36
Study 35008055 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 301
Study 35008055 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (7-day course)
Number of subjects: 301
Study 33751409 — intervention group
Group type: EXPERIMENTAL
Intervention: mERAS
Number of subjects: 189
Study 33751409 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study 35793409 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 79
Study 35793409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 32954807 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (PV) in combination with bendamustine and rituximab
Number of subjects: 0
Study 32954807 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32094326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) over the DMN
Number of subjects: 26
Study 36127866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Subvastus Approach (MSVA)
Number of subjects: 58
Study 36127866 — intervention group
Group type: COMPARATOR
Intervention: Medial Parapatellar Approach (MPA)
Number of subjects: 58
Study 32464807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo lung perfusion (EVLP)
Number of subjects: 216
Study 32464807 — intervention group
Group type: COMPARATOR
Intervention: Control (standard criteria lungs)
Number of subjects: 216
Study 34570990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous pyonex
Number of subjects: 88
Study 34448089 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV‐VG plus individual PEEP (PI group)
Number of subjects: 120
Study 34448089 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV‐VG plus 5cmH2O PEEP (PF group)
Number of subjects: 120
Study 34448089 — intervention group
Group type: EXPERIMENTAL
Intervention: VCV plus individual PEEP (VI group)
Number of subjects: 120
Study 34448089 — intervention group
Group type: COMPARATOR
Intervention: VCV plus 5cmH2O PEEP (VF group)
Number of subjects: 120
Study 33711538 — intervention group
Group type: EXPERIMENTAL
Intervention: First method for generating synthetic SNPs based on the phenotype vector
Number of subjects: 0
Study 33711538 — intervention group
Group type: EXPERIMENTAL
Intervention: Second method for generating synthetic SNPs based on real SNPs similar to the phenotype vector
Number of subjects: 0
Study 33711538 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression for GWAS
Number of subjects: 0
Study 35278807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive telephone‐based intervention for smoking cessation after discharge
Number of subjects: 530
Study 34898493 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention focusing on antimicrobial agents prescribing and resistance
Number of subjects: 69
Study 34898493 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 69
Study 34504252 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 of 0.5 to 1.0 (on-pump)
Number of subjects: 53
Study 34504252 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 of 0.3 to 0.8 (off-pump)
Number of subjects: 53
Study 34504252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall FiO2 change of 0.5
Number of subjects: 53
Study 34504252 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual ΔSvO2
Number of subjects: 53
Study 34504252 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease status
Number of subjects: 53
Study 32475183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 0
Study 32475183 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 36420908 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 440
Study 36420908 — intervention group
Group type: COMPARATOR
Intervention: Educational materials
Number of subjects: 440
Study 36420908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 440
Study 34630609 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi-Wenjing-Fang (YWF) granules (HGWD granules)
Number of subjects: 360
Study 34630609 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi-Wenjing-Fang (YWF) granules (DSD granules)
Number of subjects: 360
Study 34630609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mimetic granules of YWF)
Number of subjects: 360
Study 34630609 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (YWF granules, HGWD granules, DSD granules, and placebo)
Number of subjects: 360
Study 35059257 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyzed hydrogen-rich water (EHW)
Number of subjects: 50
Study 35059257 — intervention group
Group type: COMPARATOR
Intervention: Filtered water (FW)
Number of subjects: 50
Study 33096554 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet (HD)
Number of subjects: 40
Study 36429537 — intervention group
Group type: EXPERIMENTAL
Intervention: Technological rehabilitation (TG)
Number of subjects: 30
Study 34280013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600mg over 2h q8h (intermittent group)
Number of subjects: 9
Study 34280013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600mg over 2h (loading dose) and 1200mg over 22h (continuous group)
Number of subjects: 9
Study 32476619 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training (upright stepping)
Number of subjects: 0
Study 32476619 — intervention group
Group type: COMPARATOR
Intervention: Impairment-based training
Number of subjects: 0
Study 33564825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (600 kcal energy, 20 g protein, and micronutrient supplementation daily)
Number of subjects: 816
Study 33564825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 816
Study 32759347 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous sampling
Number of subjects: 113
Study 32759347 — intervention group
Group type: COMPARATOR
Intervention: Arterial sampling
Number of subjects: 113
Study 32186014 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Shenfu decoction
Number of subjects: 63
Study 32186014 — intervention group
Group type: COMPARATOR
Intervention: Standard medications
Number of subjects: 63
Study 34787647 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Epoprostenol (iEPO)
Number of subjects: 201
Study 34787647 — intervention group
Group type: COMPARATOR
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 201
Study 33661070 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival swab
Number of subjects: 45
Study 33661070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Number of subjects: 45
Study 33661070 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp examination
Number of subjects: 45
Study 36076163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predicting cancer-specific survival (CSS) based on multivariate Cox regression model
Number of subjects: 14138
Study 33840769 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-based hand massage therapy (experimental group)
Number of subjects: 199
Study 33840769 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 199
Study 35346044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (combined with ropivacaine)
Number of subjects: 61
Study 35346044 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (combined with ropivacaine)
Number of subjects: 61
Study 32520602 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect laryngeal biopsy forceps combined with antibiotics
Number of subjects: 20
Study 32520602 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 20
Study 32272255 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed prasugrel tablets
Number of subjects: 674
Study 32272255 — intervention group
Group type: COMPARATOR
Intervention: Integral prasugrel tablets
Number of subjects: 674
Study 36258219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 45000
Study 36258219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 45000
Study 36258219 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab + Imdevimab
Number of subjects: 45000
Study 36258219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 45000
Study 33300756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-start (FS) phase
Number of subjects: 12
Study 33300756 — intervention group
Group type: EXPERIMENTAL
Intervention: Even-pace (EP) phase
Number of subjects: 12
Study 33300756 — intervention group
Group type: EXPERIMENTAL
Intervention: End-spurt (ES) phase
Number of subjects: 12
Study 33300756 — intervention group
Group type: COMPARATOR
Intervention: Comparison of phases
Number of subjects: 12
Study 32900785 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg once daily for 8 weeks)
Number of subjects: 46